ReviewFrontiers in cell and developmental biology2026
Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection that culminates in systemic inflammation, immune dysfunction, and multiple organ failure. Despite advances in supportive care, the molecular mechanisms underlying sepsis remain incompletely understood, largely due to the complex interplay among innate immune signaling pathways rather than the activation of individual pathways in isolation. Recent evidence indicates that extensive crosstalk between toll-like receptor (TLR), NLRP3 inflammasome, cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING), and nuclear factor-kappa B (NF-κB) signaling networks orchestrates the instigation, amplification, and resolution of inflammatory responses during sepsis. These interconnected pathways collectively regulate pathogen recognition, cytokine production, inflammasome activation, type I interferon signaling, pyroptosis, and immune cell reprogramming, while simultaneously interacting with metabolic, oxidative stress, autophagic, and programmed cell death pathways. This review comprehensively examines the molecular architecture and dynamic interactions among these signaling networks, highlighting the shared adaptor proteins, regulatory feedback loops, and signaling hubs that determine the transition from protective host defense to uncontrolled hyperinflammation and subsequent immunosuppression. We further discuss how mitochondrial dysfunction, reactive oxygen species (ROS), damage-associated molecular patterns (DAMPs), epigenetic modifications, and non-coding RNAs (ncRNAs) modulate these signaling circuits and contribute to organ-specific injury in sepsis. Emerging evidence from single-cell transcriptomics, spatial multi-omics, and systems biology methods is also explored to provide a network-level understanding of immune dysregulation and identify novel biomarkers and therapeutic targets. Finally, we summarize current and emerging therapeutic strategies aimed at modulating innate immune signaling, including inhibitors of TLRs, NLRP3 inflammasome, STING, and NF-κB, as well as combination and precision medicine approaches. By integrating canonical and emerging signaling pathways into a unified molecular framework, this review provides new insights into the pathogenesis of sepsis and highlights promising directions for the advancement of targeted immunomodulatory therapies capable of cultivating clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.